title: [Epidemiological profile and antibiotic resistance of Pseudomonas aeruginosa isolates in burn and traumatology center in Tunisia over a three-year period].
abstract: BACKGROUND
  Pseudomonas aeruginosa is a known opportunistic pathogen frequently causing serious infections in burned patients.
  
  
  OBJECTIVE
  To analyze the epidemiological profile of Pseudomonas aeruginosa isolated in a Tunisian burn unit.
  
  
  METHODS
  During a 3-year period (from 01 July 2008 to 30 June 2011), 544 non repetitive strains of P. aeruginosa were isolated from burn patients. Susceptibility to antibiotics was assessed according to CA-SFM guidelines. Serotypes were identified by slide agglutination test using P.aeruginosa O antisera (Biorad). Producing carbapenemase was analyzed for 202 imipenem resistant isolates by EDTA test. Susceptibility testing data were stored in a laboratory data base using whonet 5.3 software.
  
  
  RESULTS
  The most frequent sites of isolation were cutaneous infections and blood cultures (83.4%). The percentages of resistant isolates were as follows: ceftazidime: 34%; imipenem: 37.1%, ciprofloxacin: 27.1% and amikacin: 29.6%. The most prevalent serotypes were: 011(51%), 06(17%), 03 (8%), 04(12%), 012(5%). Among the 202 imipenem resistant strains, 58% expressed a metallocarbapenemase. All theses strains were resistant to all tested antibiotics except colistin and belonged to the serotype O11.
  
  
  CONCLUSIONS
  The dissemination of carbapenemases strains must be contained by implementation of timely identification, strict isolation methods and better hygienic procedures.
authors.affiliation: Universite de Tunis, El Manar, Tunisie.
authors.forename: Ayoub
authors.initials: A
authors.lastname: Zoghlami
authors.forename: Lamia
authors.initials: L
authors.lastname: Kanzari
authors.forename: Jalel
authors.initials: J
authors.lastname: Boukadida
authors.forename: Amen Allah
authors.initials: AA
authors.lastname: Messadi
authors.forename: Abdelraouef
authors.initials: A
authors.lastname: Ghanem
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001426:Bacterial Proteins / Q000378:metabolism; D002053:Burn Units / Q000706:statistics & numerical data*; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology; D024881:Drug Resistance, Bacterial / Q000502:physiology; D006801:Humans; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000453:epidemiology* / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000201:enzymology / Q000254:growth & development / Q000302:isolation & purification*; D012703:Serotyping; D013997:Time Factors; D014194:Traumatology / Q000706:statistics & numerical data*; D014416:Tunisia / Q000453:epidemiology; D001618:beta-Lactamases / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D001618:beta-Lactamases; C063912:carbapenemase